Unraveling the complexity of cell signaling pathways can advance the understanding of various diseases. The use of 3’ RNA sequencing has been instrumental in this field, creating a need for high-throughput solutions that afford increased accuracy, specificity and sensitivity. QIAGEN's QIAseq UPX 3' Transcriptome Kit, also available as a service, addresses these requirements by providing high-throughput 3' transcriptome NGS from ultralow amounts of RNA.
Discover through inspirational stories below how QIAseq UPX 3' Transcriptome technology facilitated a deeper understanding of diabetes through gene expression and cell signaling analysis and interpretation.
Simona Chera , Ph.D.,
University of Bergen
“For us, the QIAseq UPX 3’ Transcriptome approach was a life-saver, allowing high- throughput sequencing on ultralow amounts of RNA isolated from hard-to-process samples. The pilot results obtained with QIAGEN Genomic Services exceeded our expectations. In my opinion, this is certainly an approach to keep in mind when the RNA quantity is below the minimal threshold.”
Recent compelling research by Dr. Simona Chera and her team at the Department of Clinical Science, University of Bergen, who investigated the development of human-induced pluripotent stem cells (hiPSCs) into insulin-producing pancreatic islet cells for potential use in diabetes treatment. Discover how QIAseq UPX 3' Transcriptome Kits, as well as GeneGlobe and QIAGEN Digital Insights played a fundamental role in accelerating sequencing and data analysis for this study.
Matthew Dodson, Ph.D.,
University of Arizona
"QIAGEN's UPX 3’ Transcriptome service allowed us to generate a large-scale RNA-seq data set that facilitated our discovery of key gene expression changes that drive our disease model."
Exciting new research by Dr. Matthew Dodson and Dr. Donna Zhang from the University of Arizona, who investigated the role of Nrf2 regulation in diabetic disease. Learn how QIAseq UPX 3' Transcriptome technology – as part of QIAGEN's Genomic Services – played a crucial role in establishing a connection between environmental arsenic exposure and type II diabetes.
Speakers: Matthew Dodson, Ph.D., Department of Pharmacology and Toxicology, University of Arizona and Raphael Werding, M.Sc., Genomic Services, QIAGEN
Thank you for contacting us. We will be in touch with you shortly.
* Required field